Statements (403)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
gptkb:Ophthalmology
gptkb:healthcare_professionals injection intravitreal injection oncology settings FOLFIRI regimen patients with RVO |
| gptkbp:adverse_effects_management |
hydration therapy
monitoring blood pressure managing renal function |
| gptkbp:adverse_reaction_monitoring |
required
|
| gptkbp:approves |
gptkb:2011
gptkb:2012 gptkb:European_Union gptkb:FDA gptkb:United_States cancer therapy pediatric patients |
| gptkbp:associated_with |
improved patient outcomes
decreased metastasis fewer injections over time lower risk of vision loss reduced blood supply to tumors |
| gptkbp:available_in |
vials
pre-filled syringes |
| gptkbp:available_on |
prescription medication
|
| gptkbp:benefits |
enhances quality of life
improves survival rates reduces tumor growth |
| gptkbp:can_be_combined_with |
chemotherapy
|
| gptkbp:class |
VEGF inhibitors
anti-angiogenic agent |
| gptkbp:clinical_trial |
gptkb:Bayer_Health_Care
gptkb:Ophthalmology gptkb:Europe gptkb:Asia gptkb:Bayer_AG gptkb:Canada gptkb:Oncology gptkb:United_States gptkb:Regeneron_Pharmaceuticals ongoing Phase 1 Phase II multiple countries Phase 2 Phase 3 Phase III Phase I Phase III trials real-world evidence multiple research institutions retinal vein occlusion Phase I, II, III published in medical journals head and neck cancer NCT04512345 overall survival comparative effectiveness positive efficacy acceptable safety profile choroidal neovascularization NCT03012345 NCT02212345 diabetic macular edema wet age-related macular degeneration VEGF Trap for AMD VEGF Trap for CRC VEGF Trap for DME VEGF Trap for HNSCC VEGF Trap for NSCLC VEGF Trap for RVO VEGF Trap for advanced cancer VEGF Trap for pediatric patients VEGF Trap for refractory cases VEGF Trap in combination with chemotherapy VEGF Trap in combination with immunotherapy VEGF Trap in NSCLC VEGF Trap in combination with other agents VEGF Trap vs. placebo long-term follow-up data ongoing for other cancers NCT01320356 NCT01414140 NCT02012345 NCT02512345 NCT03512345 NCT04012345 NCT05012345 |
| gptkbp:clinical_use |
oncology
ophthalmology solid tumors monthly injections treatment of vision loss treatment of wet AMD |
| gptkbp:collaborated_with |
academic institutions
research organizations clinical trial networks |
| gptkbp:collaboration |
academic institutions
healthcare providers regulatory agencies clinical research organizations |
| gptkbp:collaborations |
non-profit organizations
academic institutions pharmaceutical companies research organizations biotech firms with academic institutions clinical research organizations international health agencies |
| gptkbp:collaborator |
gptkb:Sanofi
gptkb:Bayer |
| gptkbp:competitors |
high
other VEGF inhibitors |
| gptkbp:condition |
diabetic retinopathy
myopia choroidal neovascularization |
| gptkbp:contraindication |
hypersensitivity to components
active ocular infection uncontrolled systemic disease active infection severe uncontrolled hypertension |
| gptkbp:demonstrated_efficacy_in |
improving visual acuity
reducing retinal edema |
| gptkbp:developed_by |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:discovered_by |
2000s
|
| gptkbp:dosage_form |
gptkb:Software_Solutions
monthly bi-monthly single-use vial based on body weight |
| gptkbp:dosage_frequency |
once every 4 to 8 weeks
|
| gptkbp:drug_interactions |
may interact with anticoagulants
|
| gptkbp:duration |
ongoing monitoring required
depends on response |
| gptkbp:effective_date |
gptkb:2011
|
| gptkbp:eligibility |
based on cancer stage
|
| gptkbp:feedback |
generally positive
collected for improvement |
| gptkbp:financial_stability |
high
|
| gptkbp:financial_support |
available
available for financial assistance |
| gptkbp:formulation |
gptkb:fusion
gptkb:monoclonal_antibody gptkb:liquid solution for injection intravitreal injection |
| gptkbp:funding |
gptkb:public_funding
non-profit organizations government grants pharmaceutical companies philanthropic contributions private investments private investment pharmaceutical partnerships |
| gptkbp:future_prospects |
biomarker identification
combination therapies long-term outcomes |
| gptkbp:grants |
awarded for further studies
|
| gptkbp:has_limitations |
requires careful monitoring
not effective for all cancer types potential for resistance |
| https://www.w3.org/2000/01/rdf-schema#label |
VEGF Trap
|
| gptkbp:indication |
gptkb:Ophthalmology
gptkb:Oncology gptkb:myopic_choroidal_neovascularization metastatic colorectal cancer retinal vein occlusion head and neck cancer diabetic macular edema wet age-related macular degeneration Diabetic Macular Edema Myopic Choroidal Neovascularization Retinal Vein Occlusion |
| gptkbp:influenced_by |
immune response
genetic factors tumor microenvironment previous treatments patient age comorbidities duration of RVO |
| gptkbp:influences |
tumor microenvironment
cancer progression tumor vasculature |
| gptkbp:informed_consent_required |
gptkb:true
|
| gptkbp:ingredients |
gptkb:aflibercept
|
| gptkbp:interacts_with |
other anti-VEGF therapies
|
| gptkbp:invention |
gptkb:Regeneron_Pharmaceuticals
patented |
| gptkbp:involves |
patient assessment
monitoring for side effects dosing regimen |
| gptkbp:is_a_guide_for |
gptkb:American_Academy_of_Ophthalmology
gptkb:National_Institute_for_Health_and_Care_Excellence gptkb:European_Society_of_Retina_Specialists |
| gptkbp:is_compared_to |
gptkb:Avastin
gptkb:Lucentis traditional chemotherapy |
| gptkbp:is_effective_against |
proven
improves overall survival improves survival rates reduces tumor size delays disease progression |
| gptkbp:is_monitored_by |
post-marketing surveillance
regular eye exams retinal health intraocular pressure required during treatment visual acuity changes |
| gptkbp:is_studied_in |
molecular biology
pharmacology clinical oncology |
| gptkbp:is_tested_for |
VEGF levels
circulating tumor cells tumor response markers |
| gptkbp:knockouts |
high
|
| gptkbp:launch_date |
gptkb:2012
|
| gptkbp:lifespan |
long
|
| gptkbp:market_launch |
gptkb:2012
gptkb:2013 |
| gptkbp:marketed_as |
gptkb:Europe
gptkb:Asia gptkb:Australia gptkb:Canada gptkb:Japan gptkb:North_America gptkb:United_States gptkb:Eylea gptkb:Zaltrap the name Eylea |
| gptkbp:mechanism_of_action |
inhibits angiogenesis
inhibits VEGF signaling inhibits vascular endothelial growth factor (VEGF) VEGF neutralization binds to VEGF-A |
| gptkbp:patient_education |
informed consent
important for adherence side effect management side effects information follow-up care instructions treatment expectations |
| gptkbp:patient_population |
gptkb:children
adults adolescents cancer patients adult patients patients with advanced cancer |
| gptkbp:patient_quality_of_life |
monitored in studies
|
| gptkbp:pharmacokinetics |
dose-dependent response
half-life of 4-5 days |
| gptkbp:price |
high
|
| gptkbp:project |
Phase III
Phase III trials commercialized |
| gptkbp:provides_guidance_on |
gptkb:American_Academy_of_Ophthalmology
gptkb:hospital gptkb:European_Society_of_Retina_Specialists included treatment protocols updated regularly dosing recommendations ASCO guidelines monitoring guidelines National Institute for Health and Care Excellence (NICE) NCCN guidelines AAP guidelines |
| gptkbp:publication |
peer-reviewed journals
clinical trial results efficacy studies safety studies numerous studies published mechanism studies |
| gptkbp:regulatory_compliance |
gptkb:European_Medicines_Agency_(EMA)
gptkb:FDA gptkb:European_Medicines_Agency gptkb:EMA TGA full approval conditional approval |
| gptkbp:requires |
medical supervision
|
| gptkbp:research |
long-lasting effects
improves quality of life well-tolerated in patients VEGF Trap efficacy in adolescents study VEGF Trap for pediatric cancer study VEGF Trap for retinopathy of prematurity study VEGF Trap in pediatric patients study VEGF Trap safety in children study reduces VEGF levels |
| gptkbp:research_areas |
gptkb:neurodegenerative_diseases
cardiology oncology biomarker identification combination therapies ophthalmology anti-VEGF therapies new delivery methods long-term efficacy studies patient quality of life studies |
| gptkbp:research_focus |
oncology
patient quality of life cardiovascular diseases pediatric oncology metastatic cancer angiogenesis biomarker identification combination therapies ophthalmology solid tumors safety profile ocular diseases pediatric ophthalmology treatment resistance long-term efficacy dosing regimens VEGF-related diseases |
| gptkbp:research_institutes |
various universities
various academic institutions |
| gptkbp:research_output |
positive efficacy results
safety profile established long-term effects studied |
| gptkbp:risk_factor |
thromboembolic events
infection risk systemic exposure hemorrhage risk |
| gptkbp:route_of_administration |
intravenous
intravitreal injection intraocular injection intravitreal intraocular |
| gptkbp:safety_features |
generally well tolerated
monitored in trials |
| gptkbp:safety_measures |
adverse event reporting
required during trials |
| gptkbp:sales |
increasing
|
| gptkbp:service_frequency |
monthly
varies by condition every 2 weeks every 4 weeks |
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
fatigue
nausea hypertension mandatory diarrhea bleeding gastrointestinal perforation thromboembolic events retinal detachment proteinuria intraocular pressure increase increased intraocular pressure intraocular inflammation ocular inflammation cataract formation systemic hypertension mandatory for clinical trials |
| gptkbp:storage |
refrigerated
|
| gptkbp:supply_chain |
managed by pharmaceutical distributors
|
| gptkbp:target_audience |
adults
pediatric patients |
| gptkbp:targets |
gptkb:Oncology
gptkb:vascular_endothelial_growth_factor gptkb:vascular_endothelial_growth_factor_(VEGF) ovarian cancer Vascular Endothelial Growth Factor Vascular Endothelial Growth Factor (VEGF) retinopathy of prematurity diabetic macular edema neovascular age-related macular degeneration |
| gptkbp:treatment |
improve quality of life
varies by individual patient satisfaction symptom relief quality of life improvement tumor shrinkage evaluated in studies vision improvement improved visual acuity long-term safety data vision stabilization assessed in clinical trials prevent vision loss reduced need for laser therapy reduced retinal thickness stabilized vision treatment response rate |
| gptkbp:type_of_care |
important
important for efficacy |
| gptkbp:type_of_insurance |
variable
varies by plan |
| gptkbp:used_for |
gptkb:Oncology
Colorectal Cancer treatment of cancer treatment of advanced cancer treatment of eye diseases Age-related Macular Degeneration (AMD) Diabetic Macular Edema treatment of HNSCC treatment of retinal vein occlusion (RVO) |
| gptkbp:used_in |
combination therapy
|
| gptkbp:website |
aseptic technique required
|